Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

September 02, 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

Good Early Results for Conformable, ‘Single-Shot’ Pulsed-Field Ablation Catheter

News Conference News EHRA 2024

Good Early Results for Conformable, ‘Single-Shot’ Pulsed-Field Ablation Catheter

April 16, 2024

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

August 30, 2022

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

News Conference News ACC 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

April 06, 2020

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs

News Conference News ISC 2018

More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs

January 27, 2018

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.